A process for pre ing a compound represented by formula (I), wherein R.sup.1 represents straight-chain or branched C.sub.1-5 alkyl, C.sub.1-5 haloalkyl, or C.sub.3-6 cycloalkyl, and R.sup.2 represents C.sub.1-3 alkyl or C.sub.1-3 haloalkyl.

A compound of formula (I): ##STR1## wherein: R represents hydrogen, optionally substituted alkyl or alkenyl, R.sub.1 to R.sub.8, which may be identical or different, each represents hydrogen, optionally substituted alkyl, hydroxy, acyloxy, optionally substituted amino, carboxy, optionally substituted alkoxy, or alkenyloxy, or one of R.sub.1 to R.sub.8 forms, with another of R.sub.1 to R.sub.8 that is adjacent, an alkylenedioxy group, X represents oxygen or NR.sub.16 wherein R.sub.16 represents h...

A method and catalyst system for economically producing aromatic carbonates from aromatic hydroxy compounds. In one embodiment, the present invention provides a method of carbonylating aromatic hydroxy compounds by contacting at least one aromatic hydroxy compound with oxygen and carbon monoxide in the presence of a carbonylation catalyst system that includes an effective amount of a Group VIII B metal source; an effective amount of a bromide composition; an effective amount of an activating org...

Disclosed is a process for the preparation of a compound of the formula (1) wherein R.sub.1 is unsubstituted or substituted sing reacting a compound of the formula (2) with a compound of the formula (3) in the presence of an aqueous base ransfer catalyst.

Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. ##STR1##

1,3-Azole derivatives, pharmaceutical compositions thereof and methods for regulating the function of retinoid-related receptors with 1,3-azole derivatives are disclosed. Such regulation may be useful for preventing or treating diabetes, preventing or treating hyperlipidemia, preventing or treating impaired glucose tolerance (IGT) or for preventing transition from impaired glucose tolerance to diabetes.

The present invention relates to a new substituted benzimidazoles, their preparation and their use as agents against parasitic protazoa.

Functionalized allylic olefins are condensed by metathesis using the catalyst 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ruthenium benzylidene [Ru*]. ##STR1##

Ethers and esters of cyanohydrins that contain optically detectable moieties are highly effective for detecting, monitoring, and measuring the activity of enzymes that cause the cleavage of certain types of substrates. The cyanohydrins function as proaldehydes and proketones, spontaneously converting to aldehydes and ketones, respectively, which provide a large increase in optical detectability relative to both the starting esters and ethers and the cyanohydrins.

The invention relates to organophosphorus compounds of general formula (I) wherein A corresponds to general formula (II), wherein one or more of the carbon atoms, selected from the group C.sub.3, C.sub.4, C.sub.5 and their respective substituents can be omitted, and at least one substituent of B.sub.1 to B.sub.10 is a C.sub.3-8 cycloalkyl (C.sub.0-9) alkyl group, wherein both the C.sub.3-8 cycloalkyl group and the C.sub.0-9 alkyl group can have one or more double bonds and one or two carbon atom...